Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 14/20 | 0.38 |
| ▸ | IDO1 | P14902 | 13/20 | 0.38 |
| ▸ | DHODH | Q02127 | 4/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14551984 | 1.00 | TDO2 (0.38) | TDO2IDO1DHODHKCNN4CYP1A2 | |
| SCHEMBL12324845 | 0.91 | IDO1 (0.33) | TDO2IDO1DHODH | |
| SCHEMBL12324826 | 0.79 | IDO1 (0.41) | TDO2IDO1DHODH | |
| SCHEMBL14551980 | 0.79 | IDO1 (0.41) | TDO2IDO1DHODH | |
| SCHEMBL12324843 | 0.77 | IDO1 (0.32) | TDO2IDO1 | |
| SCHEMBL14551972 | 0.76 | DHODH (0.43) | TDO2IDO1DHODH | |
| SCHEMBL12324828 | 0.76 | IDO1 (0.42) | TDO2IDO1DHODHKCNN4 | |
| SCHEMBL14551981 | 0.76 | IDO1 (0.42) | TDO2IDO1DHODHKCNN4 | |
| SCHEMBL14551973 | 0.76 | DHODH (0.43) | TDO2IDO1DHODH | |
| SCHEMBL16283155 | 0.74 | IDO1 (0.64) | TDO2IDO1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422294-B2 | Cyclic compound, method for producing cyclic compound, and method for modifying biological molecule | JNC CORPORATION (JP) | 2016-08-23 | — | — | US | disclosed |
| US-9422294-B2 | Cyclic compound, method for producing cyclic compound, and method for modifying biological molecule | JNC CORPORATION (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20140364594-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | JNC CORP (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140364594-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | JNC CORP (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8901312-B2 | Cyclic compound, method for producing cyclic compound, and method for modifying biological molecule | JNC CORPORATION (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901312-B2 | Cyclic compound, method for producing cyclic compound, and method for modifying biological molecule | JNC CORPORATION (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130011901-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | JNC CORPORATION (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130011901-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | JNC CORPORATION (JP) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364594-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | PTMS, CD38, TIMCC | TDO2 2653/4885IDO1 2209/4885DHODH 956/4885 |
| US-20130011901-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | PTMS, CD38, TIMCC | TDO2 2653/4885IDO1 2209/4885DHODH 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.